Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Laquinimod drug greatly reduces number of relapses in patients with MS

The drug laquinimod reduced the number of relapses for people with multiple sclerosis, in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology, April 9-16, 2011, in Honolulu.

12 Apr 2011

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu.

12 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

Coronary computed tomographic angiography to evaluate acute chest pain reduces hospital admissions

Hospital admissions at Stony Brook University Medical Center on Long Island were significantly reduced when using coronary computed tomographic angiography (CCTA) to evaluate patients presenting in the emergency department (ED) with acute chest pain (ACP), according to research results presented during a scientific session at the American College of Cardiology's 60th Annual Scientific Session and Expo in New Orleans on April 3.

4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Stem Cell Action Coalition issues urgent appeal to Minnesota Governor for SCNT research

The Stem Cell Action Coalition issued an urgent appeal to Minnesota Governor Mark Dayton to veto any legislation that contains any impediment to lawful embryonic stem cell research in the state.

2 Apr 2011

Brain Canada issues statement reinforcing need for government support for brain research funding

Brain Canada today issued a statement reinforcing the pressing need for targeted Federal government support for brain research funding in Canada.

2 Apr 2011

AAN honors Mayo Clinic researcher with John Dystel Prize for MS work

The American Academy of Neurology is awarding the 2011 John Dystel Prize for Multiple Sclerosis Research to Brian G. Weinshenker, MD, of the Mayo Clinic in Rochester, Minnesota and a Fellow with the AAN.

1 Apr 2011

Adeona reports $3,164,512 net revenue for 2010

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, reported its financial results for the year ended December 31, 2010, as well as updates since the beginning of the 4th quarter.

31 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Study: Marijuana use may affect cognitive skills in patients with MS

Any possible pain relief that marijuana has for people with multiple sclerosis may be outweighed by the drug's apparent negative effect on thinking skills, according to research published in the March 29, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

29 Mar 2011

Angioplasty procedures have minimal risk

Understanding that angioplasty—a medical treatment used by interventional radiologists to widen the veins in the neck and chest to improve blood flow—is safe may encourage additional studies for its use as a treatment option for individuals with multiple sclerosis, say researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

Researchers identify new mechanism underlying MS

Multiple sclerosis is a disabling autoimmune disease in which nerve fibers are attacked by the patient's own immune system. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a new mechanism that contributes to nerve fiber damage - and shown that this damage can be reversed.

28 Mar 2011

Study identifies unique adult animal stem cells that can turn into neurons

A group of scientists at Marshall University is conducting research that may someday lead to new treatments for repair of the central nervous system.

25 Mar 2011

Study finds eye movement difference in two different populations

The team, working with Sichuan University in Chengdu, China, investigated eye movements in Chinese and British people to further understanding of the brain mechanisms that control them and how they compare between different human populations.

25 Mar 2011

P&G, Teva sign partnership agreement for consumer health care

The Procter & Gamble Company and Teva Pharmaceutical Industries Ltd. today announced the signing of a master agreement to create a partnership in consumer health care by bringing together both companies' existing over-the-counter medicines and complementary capabilities to accelerate growth.

25 Mar 2011